Every promising male contraceptive target deserves the
opportunity to be evaluated as a potential next generation birth control method.
Contraceptive Accelerator Network (CAN) is a small mission-centric pharmaceutical company focused on supporting the development of non-hormonal, reversible male contraceptives. By providing the necessary resources, CAN aims to bring these innovative options to market for those who produce sperm.
|
The Contraceptive Accelerator Network, LLC (CAN) is a for-profit subsidiary of MCI with $1.0M in private investment. Working in tandem with MCI, CAN identifies promising contraceptive targets and provides essential support for testing and evaluation, paving the way for Investigational New Drug (IND)-enabling studies and clinical trials.
CAN's streamlined operations maximize efficiency and minimize costs, leveraging existing drug discovery resources to expand its project portfolio. By capitalizing on MCI's early-stage risk mitigation, CAN focuses on the most promising targets and collaborates with researchers, advisors, and external partners to accelerate the development of new sperm-targeting contraceptives. |
|
Each CAN project receives personalized attention, designed to advance the program towards clinical trials, reduce future risks, and attract follow-on investment. This approach ensures that innovative male contraceptives reach market readiness as quickly as possible.
CAN is structured such that any profits generated from the contraceptive products it develops are reinvested in MCI. This innovative structure disrupts the traditional model of contraceptive drug development in a multitude of ways:
CAN is structured such that any profits generated from the contraceptive products it develops are reinvested in MCI. This innovative structure disrupts the traditional model of contraceptive drug development in a multitude of ways:
- Supports early-stage research and development: Ensures promising projects can mature into active contraceptive programs.
- Potential for expanded funding: Allows CAN to increase its support for the male contraceptive R&D field.
- Greater affordability and accessibility: Can help ensure lower costs and wider access to male contraceptives.
- Prevents promising leads from being abandoned: Provides essential development support to avoid project abandonment.
- Acts as an incubator: Nurtures programs and seeks out mission-driven partners.
- Values transparency and collaboration: Brings a philanthropic approach to pharmaceutical development.
Male Contraceptive Initiative & Contraceptive Accelerator Network's System Map
